biOasis Technologies Ord Shs V.BTI.H

Bioasis Connections

[JDavenport]

For many years I have followed the work of the noted medical oncologist, Dr. Nancy U. Lin.  I have in my files copies of her papers that relate to the state of cancer treatments over the years.

 

Her name is on a new paper released on June 7, 2022. The paper is called, "Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era. This paper is worth reading as an overview of the current state of HER+ breast cancer treatment.

 

Notice that one of the authors of the paper is Dr. Javier Cortes, a member of the Bioasis Medical Advisory Board.

 

The authors of this paper are very influential people as evidenced by their disclosures of potential conflicts of interests, which are standard disclosures on scientific papers and can be found toward the bottom of the paper. These people are very broadly engaged in the oncology space. 

 

Have a look at Nancy Lin's disclosure Consulting or Advisory Roles:

Seattle Genetics

Puma Biotechnology

Daiichi Sankyo

Denali Therapeutics

AstraZeneca

Prelude Therapeutics

Voyager Therapeutics

Affinia Therapeutics

Pfizer

Olema Pharmaceuticals

Aleta Biotherapeutics

Artera

 

And then take a look at Dr. Cortez's Consulting or Advisory Roles:

Celgene

Cellestia Biotech

AstraZeneca

Roche

Seattle Genetics

Daiichi Sankyo

ERYTECH Pharma

Polyphor

Athenex

Lilly

SERVIER

Merck Sharp & Dohme

GlaxoSmithKline

Leuko

Clovis Oncology

Bioasis

Ellipses Pharma

Boehringer Ingelheim

HiberCell

Bioinvent

GEMoaB

Gilead Sciences

Menarini

Zymeworks

Reveal Genomics

 

Why should we have any interest in these associations? Because all of the authors are consultants and advisers to many of the top pharmaceutical companies engaged in breast cancer research and development. In addition to being on the Bioasis Medical Advisory Board, Dr. Cortez lists 24 other companies with whom he advises and consults. These companies include Daiichi Sankyo and AstraZeneca, both of which have done studies with Bioasis. 

 

Bioasis has many secret things going on. How many companies on Dr. Cortez's list, and on the other lists, are already in some sort of relationship with Bioasis? I wouldn't exclude any company right now, especially companies that have known relationships with people who are directly associated with Bioasis, which Dr. Cortez most certainly is.

 

Note, also, that Dr. Cortez is listed as the correspondent for this paper, meaning that enquiries about the paper should be directed to him. This reference is on Page 9 of the paper's PDF file. (The PDF is embedded and may be more easily read if it's downloaded first.)

 

Meanwhile, mark this post, or save a link to the paper. I think it's very possible that there may be names in those lists that may appear in Bioasis's future. The connections are there. xB3-001 plays right into the breast cancer space and may one day enable treatment of one of the major concerns expressed in the paper, HER2+ brain tumours.

 

Bioasis is massively connected. It has multiple relationships and collaborations already announced. Don't bother telling us that there's nothing going on. 

 

jd